New Stem Cell Technology to Improve Drug Safety
...even millions of patients.
Identifying drugs that can trigger heart attacks before they reach the
clinic is a major focus of ReproCELL. Current cardiotoxicity
at early stages of drug development, tend to focus on one aspect of heart cell
function -- the hERG ion channel. But there are a who...
Nationally Recognized Faculty Presents Latest Advances in Care of Patients with Breast Cancer
...- Ana Maria Gonzalez-Angulo, MD, MSc, of The University of Texas M. D. Anderson Cancer Center, will discuss the issue anthracycline related cardiotoxicity
Physicians can register for and take this accredited, virtual
e-conference course at any time beginning Tuesday, October 14, 2008 at
Also in the July 29 JNCI
...pirubicin dose associated with a 5 percent risk of cardiotoxicity
for individual patients.
Oncologists frequently...he researchers assessed patients' risk factors for cardiotoxicity
and corrected for the risk of death from all other...re of the risk of cardiotoxicity, not only because cardiotoxicity
can progress to a potentially fatal outcome if not...
Genetic Engineering and Biotechnology News reports on early ADMET use
...otential but also cardiotoxicity. The company introduced the use of neonate rat cardiomyocytes cultured in 96-well plates to monitor the potential for cardiotoxicity
of a drug candidate.
Other companies covered in the GEN article include Affymetrix, Iconix, Sovicell, Apredica, MatTek, ChanTest, and EggCentris.
Cardiotoxicity in Medical Technology
Cardiotoxicity in Biological News
A search for protection against chemotherapy cardiotoxicity
Researchers at the University of Grenoble, in France, have discovered that erythropoietin administration prevents acute cardiotoxic effects induced by doxorubicin and trastuzumab exposures. The research article describing this work entitled Erythropoietin pretreatment protects against acute chemot...
Phylonix to present at 2009 Society of Toxicology Annual Meeting
...d Otoprotection in a Zebrafish Hair Cell Model"
Tuesday, March 17, 10:36 am - 10:59 am, Room 308
"Assessment of Drug Induced cardiotoxicity
in Transparent Zebrafish"
Monday, March 16, 1:00 pm - 4:30 pm
390 Poster / Board 207
"Zebrafish: A Predictive Model for Assessing P-Glycoprotein In...
American Chemical Society's Weekly PressPac -- April 23, 2008
...ave concluded in a new overview of research on the cardiotoxicity
of anti-cancer drugs. Their review, scheduled for ...d Emanuela Salvatorelli point out that the risk of cardiotoxicity
may be higher than previously believed, especially...ative efforts that improve early identification of cardiotoxicity
and minimize the risks of cardiac events in patien...
Singulex Teams With Wyeth Pharmaceuticals to Translate Pre-Clinical Biomarker Research Into Clinical Study Design
...ple species. Singulex was
the first to identify and quantify normal levels and small changes of
cardiac troponin I, a protein biomarker used to detect cardiotoxicity
heart attacks, in human plasma.
"Singulex's technology extends the clinical utility of new and existing
biomarkers by removing the limits of det...
Cardiotoxicity in Biological Technology
Cellular Dynamics International and Roche Expand Existing Cardiotoxicity Screening Agreement
MADISON, Wis., July 1 /PRNewswire/ -- Cellular Dynamics International (CDI) and Roche announced today a significant expansion of their existing agreement to test drug development candidates for their potential to cause cardiotoxicity, or damage to heart tissue. The two-year collaboration a...
Sopherion Therapeutics Secures $55 Million in Series C Funding
...inical development program for its lead product candidate, Myocet(TM). Myocet is a liposomal formulation of doxorubicin designed to reduce the risk of cardiotoxicity
while preserving antitumor efficacy.
In January 2008, Zoticon Bioventures in-licensed Myocet and provided funding of $20 million to Sopherion and...
Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
...nt-related symptomatic congestive heart failure. This is noteworthy because cardiotoxicity
is a common and therapy-limiting adverse event of the anthracycline class o... a liposomal delivery system for doxorubicin designed to reduce the risk of cardiotoxicity
associated with doxorubicin while preserving its antitumor efficacy. It is...
Lilly to Acquire ImClone Systems in $6.5 Billion Transaction
...on Therapy and Cisplatin
-- The safety of ERBITUX in combination with radiation therapy and
cisplatin has not been established
- Death and serious cardiotoxicity
were observed in a single-arm trial
with ERBITUX, radiation therapy, and cisplatin (100 mg/m2) in patients with
locally advanced squamous cell carcino...
First Taxane-Based Non-Anthracycline Containing Chemotherapy in Combination With Herceptin (TCH) for HER2 Positive Early Breast Cancer Patients Obtains Approval From the FDA
...Disease-Free Survival (DFS) and Overall Survival (OS), compared to AC-T
(doxorubicin and cyclophosphamide followed by docetaxel) and a 5-fold lower
compared to AC-TH (AC-T + Herceptin) in women receiving adjuvant therapy for HER2-positive ESBC
EDMONTON, Canada, May 29 /PRNewswire/...
Increased Drug Related Cardiac Toxicity Leads Gwathmey Preclinical Testing Services to Create Novel Cardionomics(TM) Services for Preclinical Cardiac Safety Screening of Drug Candidates
...rdiac toxicity in new
drugs at the World Pharmaceutical Congress in Philadelphia on May 12, 2008
when he gives a presentation entitled: "Evaluation of cardiotoxicity
Novel Molecular Therapies."
"The topic of cardiac safety of new drugs is one that has long been a
priority for pharmaceutical companies. Cardiac ...
ReachBio Partners with Axiogenesis to Distribute Novel Cell-Based Products in North America
...plates, and pre-seeded coverslips. Branded as Cor.AT
cells, these cardiomyocytes have been rigorously functionally qualified and
found to be ideal for cardiotoxicity
screening, electrophysiology studies,
and as a cellular model system for hypertrophic cardiomyopathy. Pure
ventricular cardiomyocytes (Cor.VE) are als...
Kosan's Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer
...mood that resolved in a single day. Noticeably absent were
toxicities associated with conventional chemotherapy, including alopecia,
and peripheral neuropathy.
Accrual is continuing in this Phase 2 trial. Up to 20 additional
patients are anticipated to be treated with the Injectab...